S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
Log in

Cambrex Stock Price, Forecast & Analysis (NYSE:CBM)

$59.92
+0.10 (+0.17 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$59.83
Now: $59.92
$59.91
50-Day Range
$59.50
MA: $59.69
$59.86
52-Week Range
$33.80
Now: $59.92
$60.29
Volume144,958 shs
Average Volume426,032 shs
Market Capitalization$2.02 billion
P/E Ratio21.63
Dividend YieldN/A
Beta2.17
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$3.91 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$2.02 billion
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.


Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a net margin of 5.96% and a return on equity of 5.38%. The firm's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the company posted $0.76 earnings per share. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Cambrex.

What price target have analysts set for CBM?

5 brokerages have issued 12-month target prices for Cambrex's shares. Their forecasts range from $43.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.6%. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

Media headlines about CBM stock have trended positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cambrex earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Cambrex.

Are investors shorting Cambrex?

Cambrex saw a drop in short interest in October. As of October 31st, there was short interest totalling 1,110,000 shares, a drop of 5.1% from the September 30th total of 1,170,000 shares. Based on an average trading volume of 542,800 shares, the short-interest ratio is presently 2.0 days. Approximately 3.3% of the company's stock are sold short. View Cambrex's Current Options Chain.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), NVIDIA (NVDA), Intel (INTC), Juno Therapeutics (JUNO), Under Armour (UAA) and Broadcom (AVGO).

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include GW&K Investment Management LLC (1.35%), Gabelli Funds LLC (0.72%), GABELLI & Co INVESTMENT ADVISERS INC. (0.46%), Rhumbline Advisers (0.32%), New York State Teachers Retirement System (0.27%) and Summit Creek Advisors LLC (0.26%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

Which institutional investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Summit Creek Advisors LLC, Trillium Asset Management LLC, Confluence Investment Management LLC, Envestnet Asset Management Inc., First Trust Advisors LP, Tocqueville Asset Management L.P. and IMA Wealth Inc.. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen and Shawn Cavanagh. View Insider Buying and Selling for Cambrex.

Which institutional investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Exane Asset Management, Dupont Capital Management Corp, Harvest Management LLC, GW&K Investment Management LLC, Tokio Marine Asset Management Co. Ltd. and Russell Investments Group Ltd.. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $59.92.

How big of a company is Cambrex?

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com/.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel